(Senior) Medical Science Liaison - Mid South - GA, KY, or East TN
Tempus AI
Summary
We are looking for a high-performing and experienced Medical Science Liaison (MSL) or Senior Medical Science Liaison (Sr. MSL) to support the commercial and educational objectives of the company. We are seeking a field-based MSL with a strong clinical and scientific background in oncology, genomic testing, and excellent communication skills to educate healthcare providers about Tempus assays and technologies. We are considering candidates based in GA, KY, or East TN.
Job description
Responsibilities
- Function as a sales and commercial team support and a regional expert with respect to Tempus oncology assays, promoting exchange of clinical/scientific/technical information with regional KOLs and other physicians in the field of oncology
- Facilitate education of a broader healthcare provider community within the region (KOLs, community physicians, medical directors, and other HCPs) regarding Tempus oncology products via in-person or virtual presentations. This will include proactive and reactive communication of scientific data
- Provide scientific education for internal stakeholders in collaboration with Learning & Development team
- Attend conferences and other key meetings and provide comprehensive meeting synopses and summaries of high-impact abstracts/posters/oral presentations
- Continuously update internal stakeholders on relevant medical and scientific knowledge as well as proactively sharing market intelligence
Required Skills
- Fundamental understanding of the field of molecular oncology and related patient management algorithms
- Existing KOL relationships in the field of oncology
- Working knowledge of genomic laboratory-developed testing (LDT); familiarity with CLIA-88', CAP, Sunshine Act (2013)
- Public speaking skills and ability to effectively communicate relevant scientific topics and concepts
- Exceptional interpersonal communication skills, strong inter-, and intradepartmental management skills, ability to educate and train
- Self-starter with an ownership mindset able to work and deliver on tight timelines
- Ability to travel (up to 50%)
Education and Experience
- Advanced scientific or medical degree (PhD, PharmD, MD, MSN, BSN)
- Basic understanding of oncology required; basic understanding of molecular testing strongly preferred.
Preferred Qualifications
- 1+ years of MSL experience in diagnostics, biotech or pharmaceutical industries.
Requirements
- Advanced scientific or medical degree (PhD, PharmD, MD, MSN, BSN)
- Fundamental understanding of the field of molecular oncology and related patient management algorithms
- Existing KOL relationships in the field of oncology
- Working knowledge of genomic laboratory-developed testing (LDT)
- Familiarity with CLIA-88', CAP, Sunshine Act (2013)
- Public speaking skills and ability to effectively communicate relevant scientific topics and concepts
- Exceptional interpersonal communication skills, strong inter- and intradepartmental management skills, ability to educate and train
- Self-starter with an ownership mindset able to work and deliver on tight timelines
- Ability to travel (up to 50%)
- Basic understanding of oncology required
- Basic understanding of molecular testing strongly preferred
- 1+ years of MSL experience in diagnostics, biotech or pharmaceutical industries
Company overview
Tempus AI, Inc. (NASDAQ: TEM) is a pioneering healthcare technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company was established after Lefkofsky's wife was diagnosed with breast cancer, driving his mission to revolutionize cancer care through technology and artificial intelligence. Tempus specializes in applying AI to advance precision medicine by collecting and analyzing vast amounts of molecular, clinical, and genomic data. The company operates across multiple therapeutic areas including oncology, cardiology, radiology, neurology, psychiatry, and dermatology. Tempus provides comprehensive diagnostic services including next-generation sequencing (NGS), PCR profiling, and molecular pathology testing. Its AI-powered platform enables physicians to make real-time, data-driven decisions for personalized patient care and targeted therapies. The company went public in June 2024 and has expanded globally with operations in multiple countries. Tempus continues to innovate at the intersection of healthcare and artificial intelligence, aiming to ensure patients receive the right treatments at the right time for improved health outcomes.